Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
202 hedge funds and large institutions have $2.57B invested in Intercept Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 86 increasing their positions, 43 reducing their positions, and 34 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 43
32% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 34
23% more capital invested
Capital invested by funds: $2.1B → $2.57B (+$473M)
6% more funds holding
Funds holding: 191 → 202 (+11)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
48% less call options, than puts
Call options by funds: $237M | Put options by funds: $460M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
+$72.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$62.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$57.8M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$40.1M |
| 5 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$29.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$60.5M |
| 2 |
JP Morgan Chase
New York
|
-$54.1M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$28.8M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$24.1M |
| 5 |
ECP
Elk Creek Partners
Denver,
Colorado
|
-$20.9M |
ICPT Hedge Fund Activity: Q1 2019 in Review
202 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2019, worth a combined $2.57B — up 23% from $2.1B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new ICPT positions and 34 closed out — a net gain of 11 holders — while 86 added to existing stakes and 43 trimmed.
The largest buyer was Senvest Management, opening a new position worth an estimated $72.4M. The largest seller was Boxer Capital, exiting entirely with an estimated $60.5M sold.
- 202 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2019, up from 191 in Q4 2018.
- Funds reported $2.57B of Intercept Pharmaceuticals, Inc. stock for Q1 2019, up 23% quarter-over-quarter.
- 45 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2019 and 34 closed out, a net change of +11 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2019 was Senvest Management, an estimated $72.4M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q1 2019 was Boxer Capital, an estimated $60.5M sold.
Based on aggregated 13F filings for Q1 2019.